Transformed Indolent Lymphoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2019-04-23
Clinical Trial Update: Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL [Phase 2]
Phase 2 trial evaluating ibrutinib with bendamustine and rituximab for relapsed/refractory aggressive B-cell lymphomas, with several DLBCL-r…